In an unprecedented study conducted at UCLA and 29 other sites worldwide, Keytruda (pembrolizumab) was found to be effective in the treatment of patients with advanced non-small cell lung cancer
- U.S. Food and Drug Administration has approved the groundbreaking immunotherapy drug Keytruda (pembrolizumab) to treat advanced non-small cell lung cancer (NSCLC)
- Three-year international study led by UCLA showed responses which were generally of long duration with the drug in patients with NSCLC
- Results also found the drug to be generally better tolerated than typical chemotherapies
- The study identified which patients were most likely to benefit by evaluating characteristics of patients’ tumors, leading to simultaneous approval of a test to select patients most likely to benefit from the drug
The U.S. Food and Drug Administration today approved the breakthrough drug Keytruda to treat advanced non-small cell lung cancer, signaling a paradigm shift in the way the deadliest of all cancers is treated.
In the largest study published to date using immunotherapy to treat lung cancer, the drug Keytruda (pembrolizumab) was tested on approximately 500 patients with non-small cell lung cancer. Because so many of the patients in the study showed significant long-lasting responses, in October 2014 the FDA granted the drug “breakthrough therapy” status for use in lung cancer, allowing it to be fast-tracked for approval.
“The approval of this drug and a test to identify patients most likely to benefit has the potential to transform the way that lung cancer is treated,” said Dr. Edward Garon, the study’s principal investigator and a researcher at UCLA’s Jonsson Comprehensive Cancer Center. “The quality and duration of disease response that was seen in the trial had previously been extremely rare in lung cancer. For people battling this deadly disease, this approach provides real hope of long-lasting responses while avoiding the toxicities of typical chemotherapy.”
The response rate and duration of response for Keytruda were much greater than for drugs traditionally used to treat lung cancer. In the three-year clinical trial, the overall response rate (the percentage of people in whom tumors were substantially reduced in size) was 19 percent. In people who responded to treatment, the average duration of response exceeded one year, a remarkable advance in this difficult disease.
Keytruda, a drug that has already been proven to extend the lives of people with advanced melanoma, is an antibody that targets the protein PD-1, which is expressed by immune cells. When it binds to the another protein called PD-L1, PD-1 acts as an immune checkpoint, dampening the immune system’s T cells which otherwise could attack cancer cells, said Garon, who also is an associate professor of hematology-oncology at the David Geffen School of Medicine at UCLA.
Some tumors are able to evade an immune response by expressing high levels of PD-L1. So by blocking the interaction between PD-1 and PD-L1, Keytruda in effect enables the patient’s immune system to attack the cancer.
Since PD-L1 binding to PD-1 prevents the T cells from attacking cells, it was thought that higher levels of PD-L1 in tumors could correlate with favorable clinical outcomes with PD-1 inhibitor treatment. Approximately a quarter of screened patients in the trial had PD-L1 expression in at least half of their tumor cells. Among these patients, the overall response rate was nearly 50 percent. The study was the first to validate that clinical outcomes with this class of drug was directly associated with the level of PD-L1 expression.
Judith Gasson, director of the Jonsson Cancer Center and senior associate dean for research at the David Geffen School of Medicine at UCLA, said researchers have long hoped to develop an effective and lasting immunotherapy to fight cancer.
“We have long believed that harnessing the power of our own immune systems would dramatically alter cancer treatment,” she said. “Based upon the pioneering work conducted at UCLA, we are beginning to see the clinical benefits of this research in the most challenging cancers.”
Lung cancer is the leading cause of cancer deaths worldwide; the American Lung Association estimates more than 158,000 people in the U.S. will die from the disease this year alone. Non-small cell lung cancer accounts for approximately 85 percent of all lung cancers.
Further research into its use in other types of cancer is ongoing, as are efforts to combine Keytruda with other drugs to increase the percentage of patients who could benefit from immunotherapy.
The Latest on: Lung Cancer
via Google News
The Latest on: Lung Cancer
- PGA golfer Jason Day shares personal story of mother's battle with lung canceron November 27, 2020 at 8:26 pm
PGA star Jason Day was the world's number-one ranked golfer in 2015. It was the same year his mother, Dening, was diagnosed with cancer.
- Lung Cancer Screening Software Market May See a Big Move : CureMetrix, Siemens Healthcare, Thynk Healthon November 27, 2020 at 11:37 am
Latest Report Available at Advance Market Analytics, "Lung Cancer Screening Software Market" provides pin-point analysis for changing competitive dynamics and a forward looking perspective on ...
- Memorial Hospital rolls out new robot-assisted lung cancer screen technologyon November 27, 2020 at 11:32 am
Memorial Hospital of Jacksonville will be offering a new way to detect long cancer earlier and with greater accuracy, the hospital said Wednesday.
- Women More Likely to Survive Lung Cancer After Surgery: Studyon November 27, 2020 at 7:18 am
Women have higher survival rates after lung cancer surgery than men, according to a new study. Previous research on sex differences in survival after lung cancer treatment has yielded conflicting ...
- Covid is masking the symptoms of deadliest cancer in UK – the 10 signs you must never ignoreon November 27, 2020 at 5:10 am
COVID-19 is masking the symptoms of the deadliest cancer in UK, experts say. Lung cancer, which kills more than 35,300 Brits a year, has very similar characteristics to the coronavirus. The most ...
- Lung cancer: Nodules and distended veins are some of the lesser-known signs of the diseaseon November 26, 2020 at 1:39 am
LUNG cancer is one of the most common and serious types of cancer, with around 47,000 people diagnosed with the condition every year in the UK. But warning signs of the disease do not always present ...
- A Perfect Match: Molecular Tests Developed at MSK Guide Personalized Treatment for Lung Canceron November 25, 2020 at 1:23 pm
For personalized treatment to work, it’s important to analyze each person’s tumor for genetic mutations and find the best drugs to target those mutations.
- Engineered 'stealth bomber' virus could be new weapon against metastatic canceron November 25, 2020 at 11:10 am
Many cancer researchers can claim to have devised "smart bombs." What has been missing is the stealth bomber—a delivery system that can slip through the body's radar defenses.
- Digital help for lung cancer patientson November 25, 2020 at 8:30 am
A look at how creating 'digital twins' - a virtual or computer-based replica of a person that looks and behaves like that person - could help treat lung cancer One billion people. This is the number ...
- ALK Positive Lung Cancer Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2026on November 25, 2020 at 8:12 am
The report provides revenue of the global ALK Positive Lung Cancer Treatment market for the period 2016-2026, considering 2019 as the base year and 2026 as the forecast year. The report also provides ...
via Bing News